U.S. patent application number 14/962197 was filed with the patent office on 2016-06-16 for antiviral agents.
The applicant listed for this patent is Southern Research Institute. Invention is credited to Mark J. Suto.
Application Number | 20160166557 14/962197 |
Document ID | / |
Family ID | 55168367 |
Filed Date | 2016-06-16 |
United States Patent
Application |
20160166557 |
Kind Code |
A1 |
Suto; Mark J. |
June 16, 2016 |
ANTIVIRAL AGENTS
Abstract
A method for treating or preventing a norovirus, such as Norwalk
virus, infection in a subject, which comprises administering to
said subject in need thereof a therapeutically effective amount of
at least one compound selected from the group consisting of:
##STR00001## a pharmaceutically acceptable salt thereof or solvate
thereof or mixtures thereof. The subject can be an animal,
particularly mammals and more particularly humans and companion
animals such as cats and dogs.
Inventors: |
Suto; Mark J.; (Birmingham,
AL) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Southern Research Institute |
Birmingham |
AL |
US |
|
|
Family ID: |
55168367 |
Appl. No.: |
14/962197 |
Filed: |
December 8, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62089933 |
Dec 10, 2014 |
|
|
|
Current U.S.
Class: |
514/290 ;
514/338 |
Current CPC
Class: |
A61K 31/4439 20130101;
A61P 31/12 20180101; A61K 31/435 20130101 |
International
Class: |
A61K 31/4439 20060101
A61K031/4439; A61K 31/435 20060101 A61K031/435 |
Claims
1. A method for treating or preventing a Norovirus infection in a
subject, which comprises administering to said subject in need
thereof a therapeutically effective amount of at least one compound
selected from the group consisting of: ##STR00008## a
pharmaceutically acceptable salt thereof or solvate thereof or
mixtures thereof.
2. The method according to claim 1, wherein said compound is
##STR00009## a pharmaceutically acceptable salt thereof or solvate
thereof.
3. The method according to claim 1, wherein said compound is:
##STR00010## a pharmaceutically acceptable salt thereof or solvate
thereof.
4. The method according to claim 1 wherein said Norovirus is
Norwalk virus.
5. The method according to claim 2 wherein said Norovirus is
Norwalk virus.
6. The method according to claim 3 wherein said Norovirus is
Norwalk virus.
7. The method according to 1, wherein said subject is an
animal.
8. The method according to 2, wherein said subject is an
animal.
9. The method according to 3, wherein said subject is an
animal.
10. The method according to 4, wherein said subject is an
animal.
11. The method according to 5, wherein said subject is an
animal.
12. The method according to 6, wherein said subject is an
animal.
13. The method according to claim 1, wherein said subject is a
human.
14. The method according to claim 2, wherein said subject is a
human.
15. The method according to claim 3, wherein said subject is a
human.
17. The method according to claim 4, wherein said subject is a
human.
18. The method according to claim 5, wherein said subject is a
human.
19. The method according to claim 6, wherein said subject is a
human.
20. The method according to claim 1, wherein said subject is a
companion animal.
Description
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims priority under 35 U.S.C.
.sctn.119(e) to U.S. Provisional Application No. 62/089,933 filed
on Dec. 10, 2014, the entire contents of which are hereby
incorporated by reference.
TECHNICAL FIELD
[0002] The present disclosure relates to treating or preventing
viral infection from Norovirus by administering a therapeutically
effective amount of a compound, pharmaceutically acceptable salt
thereof or solvate thereof.
BACKGROUND OF DISCLOSURE
[0003] Norovirus is a very contagious virus. You can get a
norovirus infection from an infected person, contaminated food or
water, or by touching contaminated surfaces. The virus causes your
stomach or intestines or both to become inflamed (acute
gastroenteritis) leading to stomach pain, nausea, and diarrhea.
[0004] Anyone can be infected with Norovirus. Also, you can become
infected many times in your life and can be serious, especially for
young children and older adults.
[0005] Norovirus is the most common cause of acute gastroenteritis
in the United States. Each year, it causes 19-21 million illnesses
and contributes to 56,000-71,000 hospitalizations and 570-800
deaths. Norovirus is also the most common cause of
foodborne-disease outbreaks in the United States.
SUMMARY OF DISCLOSURE
[0006] The present disclosure relates to treating or preventing
viral infection from certain viral infections, and in particular,
Norovirus by administering to a subject in need thereof a
therapeutically effective amount of Compound 1 or Compound 2,
identified below, or a pharmaceutically acceptable salt thereof or
solvate thereof. The virus treated according to this disclosure
includes Norovirus. The subjects treated include animals,
particularly mammals and more particularly humans and companion
animals such as cats and dogs.
[0007] According to the present disclosure, a therapeutically
effective amount of at least one compound selected from the group
consisting of Compound 1 or Compound 2 is administered to a subject
in need thereof:
##STR00002## [0008]
4-Chloro-1-((4-methoxy-3,5-dimethylpyridin-2yl)methyl)-1H-benzo[d]imidazo-
-6-amine
[0008] ##STR00003## [0009]
N-((2R)-1,4-Dioxan-2-ylmethyl)-N-methyl-N'-[3-(1-methyl-1H-pyrazol-4-yl)--
5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]sulfamide;
[0010] a pharmaceutically acceptable salt thereof or solvate
thereof or mixtures thereof.
BEST AND VARIOUS MODES FOR CARRYING OUT DISCLOSURE
[0011] The present disclosure is concerned with a process for
treating or preventing a viral infection in a subject, wherein the
viral infection is from Norovirus, such as Norwalk virus. The
process comprises administering to the subject in need thereof a
therapeutically effective amount of at least one compound
represented by the formulae:
##STR00004##
a pharmaceutically acceptable salt thereof or solvate thereof or
mixtures thereof.
[0012] It is of course understood that the compounds of the present
disclosure relate to all optical isomers and stereo-isomers at the
various possible atoms of the molecule, unless specified
otherwise.
[0013] "Pharmaceutically acceptable salts" refer to derivatives of
the disclosed compounds wherein the parent compound is modified by
making acid or base salts thereof. The compounds of this disclosure
form acid and base addition salts with a wide variety of organic
and inorganic acids and bases and includes the physiologically
acceptable salts which are often used in pharmaceutical chemistry.
Such salts are also part of this disclosure. Typical inorganic
acids used to form such salts include hydrochloric, hydrobromic,
hydroiodic, nitric, sulfuric, phosphoric, hypophosphoric and the
like. Salts derived from organic acids, such as aliphatic mono and
dicarboxylic acids, phenyl substituted alkonic acids,
hydroxyalkanoic and hydroxyalkandioic acids, aromatic acids,
aliphatic and aromatic sulfonic acids may also be used. Such
pharmaceutically acceptable salts thus include acetate,
phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate,
chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate,
methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, bromide,
isobutyrate, phenylbutyrate, .beta.-hydroxybutyrate,
butyne-1,4-dioate, hexyne-1,4-dioate, cabrate, caprylate, chloride,
cinnamate, citrate, formate, fumarate, glycollate, heptanoate,
hippurate, lactate, malate, maleate, hydroxymaleate, malonate,
mandelate, mesylate, nicotinate, isonicotinate, nitrate, oxalate,
phthalate, teraphthalate, phosphate, monohydrogenphosphate,
dihydrogenphosphate, metaphosphate, pyrophosphate, propiolate,
propionate, phenylpropionate, salicylate, sebacate, succinate,
suberate, sulfate, bisulfate, pyrosulfate, sulfite, bisulfite,
sulfonate, benzene-sulfonate, p-bromobenzenesulfonate,
chlorobenzenesulfonate, ethanesulfonate, 2-hydroxyethanesulfonate,
methanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate,
p-toleunesulfonate, xylenesulfonate, tartarate, and the like.
[0014] Bases commonly used for formation of salts include ammonium
hydroxide and alkali and alkaline earth metal hydroxides,
carbonates, as well as aliphatic and primary, secondary and
tertiary amines, aliphatic diamines. Bases especially useful in the
preparation of addition salts include sodium hydroxide, potassium
hydroxide, ammonium hydroxide, potassium carbonate, methylamine,
diethylamine, and ethylene diamine.
[0015] "Solvates" refer to the compound formed by the interaction
of a solvent and a solute and includes hydrates. Solvates are
usually crystalline solid adducts containing solvent molecules
within the crystal structure, in either stoichiometric or
non-stoichiometric proportions.
[0016] The terms "effective amount" or "therapeutically effective
amount" refer to an amount of the compound of the disclosure
sufficient to provide a benefit in the treatment or prevention of
viral disease, to delay or minimize symptoms associated with viral
infection or viral-induced disease, or to cure or ameliorate the
disease or infection or cause thereof. In particular, a
therapeutically effective amount means an amount sufficient to
provide a therapeutic benefit in vivo. Used in connection with an
amount of a compound of the disclosure, the term preferably
encompasses a non-toxic amount that improves overall therapy,
reduces or avoids symptoms or causes of disease, or enhances the
therapeutic efficacy of or synergies with another therapeutic
agent.
[0017] The term "treating" refers to relieving the disease,
disorder, or condition, i.e., causing regression of the disease,
disorder, and/or condition. The term "preventing" refers to
preventing a disease, disorder, or condition from occurring in a
human or an animal that may be predisposed to the disease, disorder
and/or condition, but has not yet been diagnosed as having it;
and/or inhibiting the disease, disorder, or condition, i.e.,
arresting its development.
[0018] The compounds employed according to the present disclosure
are readily available commercially and therefore a discussion of
their preparation is not necessary.
[0019] It was surprisingly found according to the present
disclosure that the above compounds are active against Norovirus.
Compounds 1 and 2 were found to be active in the primary screen and
the data confirmed in the secondary assay, as disclosed below.
[0020] However, they did not have activity in any of the other
viruses tested, which include Herpes Simpex Virus 1 and 2, Human
cytomegalovirus, Yellow fever virus, Rift valley fever virus,
tacaribe virus, polio virus, Venezuelan equine encephalalitis
virus, Vaccina virus, Hepatitis B and C virus, and
Adenorovirusirus-5.
Method of Testing:
Primary Anti-Norovirus Assay--In-Vitro Antiviral Screening RNA
Hybridization (Replicon)
[0021] Antiviral activity against a human Norovirus (Norovirus) is
assessed in a 3-day assay using the stably-expressing human
Norovirus replicon cell line, HG23 (genogroup I, genomic length;
parental cell line, HuH7) (Chang, et al., 2006, Virol. 353:463)
maintained as sub-confluent cultures on 96-well plates. Typically,
4 doses (10-fold or 3-fold steps), in triplicate are used.
Antiviral activity is determined by blot hybridization analysis of
intracellular Norovirus RNA (normalized to the level of cellular
.quadrature.-actin RNA in each culture sample). Cytotoxicity is
assessed by neutral red dye uptake in cultures maintained in
parallel plates (Korba and Gerin, 1992, Antivir. Res. 19:55).
[0022] EC.sub.50, EC.sub.90 and CC.sub.50 values are calculated by
linear regression analysis (MS EXCEL.RTM., QuattroPro.RTM.) using
data combined from all treated cultures (Korba & Gerin, 1992,
Antivir. Res. 19:55; Okuse, et al., 2005, Antivir. Res. 65:23).
Standard deviations for EC.sub.50 and EC.sub.90 values are
calculated from the standard errors generated by the regression
analyses. EC.sub.50 and EC.sub.90 are drug concentrations at which
a 2-fold, or a 10-fold depression of intracellular Norovirus RNA
(relative to the average levels in untreated cultures),
respectively, is observed. CC.sub.50 is the drug concentration at
which a 2-fold lower level of neutral red dye uptake (relative to
the average levels in untreated cultures) is observed. The
Selectivity index (S.I.) is calculated as CC.sub.50/EC.sub.50.
Recombinant human interferon 2b (PBL laboratories, Inc.) is used as
an assay control.
Secondary Anti-Norvirus Assay--Quantitative Polymerase Chain
Reaction (Replicon)/Neutral Red (Toxicity)
[0023] The secondary anti-Norovirus assay is conducted as described
for the primary assay above. Norovirus RNA is quantified using a
real time PCR method (Chang, et al., 2006, Virol. 353:463),
normalized to the level of cellular .quadrature.-actin RNA in each
culture sample.
TABLE-US-00001 In-Vitro Antiviral Screening RNA Hybridization
(Replicon) Virus Screened: Norvirus Virus Stain: GT.sub.1 Cell
Line: HG.sub.23 Vehicle: DMSO Drug Conc. Range: 0.1-100
.quadrature.M Control Conc. Range: 1.1-300 .quadrature.M Control
Drug Name EC.sub.50 EC.sub.90 CC.sub.50 Sl.sub.50 Sl.sub.90
2'C-methyl cytidine 6.2 19 300 >48 >16 Compound 1 0.617 7.5
>100 >162 >13 Compound 2 0.331 0.986 35 106 35
EC.sub.50--compound concentration that reduces viral replication by
50% EC.sub.90--compound concentration that reduces viral
replication by 90% CC.sub.50--compound concentration that reduces
cell viability by 50% Sl.sub.50--CC.sub.50/EC.sub.50
Sl.sub.90--CC.sub.50/EC.sub.90
TABLE-US-00002 Quantitative Polymerase Chain Reaction
(Replicon)/Neutral Red (Toxicity) Virus Screened: NOROVIRUS Virus
Stain: GT.sub.1 Cell Line: HG.sub.23 Vehicle: DMSO Drug Conc.
Range: 0.1-500 .quadrature.M Control Conc. Range: 1.1-300
.quadrature.M Control Drug Name EC.sub.50 EC.sub.90 CC.sub.50
Sl.sub.50 Sl.sub.90 2'C-methyl cytidine 6.0 18 >300 >50
>17 Compound 1 1.4 8.5 >50 >36 >6 Compound 2 0.641 1.4
28 44 20 EC.sub.50--compound concentration that reduces viral
replication by 50% EC.sub.90--compound concentration that reduces
viral replication by 90% CC.sub.50--compound concentration that
reduces cell viability by 50% Sl.sub.50--CC.sub.50/EC.sub.50
Sl.sub.90--CC.sub.50/EC.sub.90
[0024] Exemplary embodiments according to the present disclosure
are;
Embodiment 1
[0025] A method for treating or preventing a Norovirus infection in
a subject, which comprises administering to said subject in need
thereof a therapeutically effective amount of at least one compound
selected from the group consisting of:
##STR00005##
a pharmaceutically acceptable salt thereof or solvate thereof or
mixtures thereof.
Embodiment 2
[0026] The method according to Embodiment 1, wherein said compound
is
##STR00006##
a pharmaceutically acceptable salt thereof or solvate thereof.
Embodiment 3
[0027] The method according to Embodiment 1, wherein said compound
is:
##STR00007##
a pharmaceutically acceptable salt thereof or solvate thereof.
Embodiment 4
[0028] The method according to any one of Embodiments 1, 2 or 3,
wherein said subject is an animal.
Embodiment 5
[0029] The method according to any one of Embodiments 1, 2 or 3,
wherein said subject is a human.
Embodiment 6
[0030] The method according to any one of claim 1, 2 or 3, wherein
said subject is a companion animal.
Embodiment 7
[0031] The method according to any one of Embodiments 1, 2, 3, 4, 5
or 6 wherein said Norovirus is Norwalk virus.
[0032] The compounds of the present disclosure can be administered
by any conventional means available for use in conjunction with
pharmaceuticals, either as individual therapeutic agents or in a
combination of therapeutic agents. They can be administered alone,
but generally administered with a pharmaceutical carrier selected
on the basis of the chosen route of administration and standard
pharmaceutical practice. The compounds can also be administered in
conjunction with other therapeutic agents.
[0033] The pharmaceutically acceptable carriers described herein,
for example, vehicles, adjuvants, excipients, or diluents, are
well-known to those who are skilled in the art. Typically, the
pharmaceutically acceptable carrier is chemically inert to the
active compounds and has no detrimental side effects or toxicity
under the conditions of use. The pharmaceutically acceptable
carriers can include polymers and polymer matrices.
[0034] The compounds of this disclosure can be administered by any
conventional method available for use in conjunction with
pharmaceuticals, either as individual therapeutic agents or in a
combination of therapeutic agents.
[0035] The dosage administered will, of course, vary depending upon
known factors, such as the pharmacodynamic characteristics of the
particular agent and its mode and route of administration; the age,
health and weight of the recipient; the nature and extent of the
symptoms; the kind of concurrent treatment; the frequency of
treatment; and the effect desired. A daily dosage of active
ingredient can be expected to be about 0.001 to 1000 milligrams
(mg) per kilogram (kg) of body weight, with the preferred dose
being 0.1 to about 30 mg/kg.
[0036] Dosage forms (compositions suitable for administration)
typically contain from about 1 mg to about 500 mg of active
ingredient per unit. In these pharmaceutical compositions, the
active ingredient will ordinarily be present in an amount of about
0.5-95% weight based on the total weight of the composition.
[0037] The active ingredient can be administered orally in solid
dosage forms, such as capsules, tablets, and powders, or in liquid
dosage forms, such as elixirs, syrups and suspensions. It can also
be administered parenterally, in sterile liquid dosage forms. The
active ingredient can also be administered intranasally (nose
drops) or by inhalation of a drug powder mist. Other dosage forms
are potentially possible such as administration transdermally, via
patch mechanism or ointment.
[0038] Formulations suitable for oral administration can consist of
(a) liquid solutions, such as an effective amount of the compound
dissolved in diluents, such as water, saline, or orange juice; (b)
capsules, sachets, tablets, lozenges, and troches, each containing
a predetermined amount of the active ingredient, as solids or
granules; (c) powders; (d) suspensions in an appropriate liquid;
and (e) suitable emulsions. Liquid formulations may include
diluents, such as water and alcohols, for example, ethanol, benzyl
alcohol, propylene glycol, glycerin, and the polyethylene alcohols,
either with or without the addition of a pharmaceutically
acceptable surfactant, suspending agent, or emulsifying agent.
Capsule forms can be of the ordinary hard- or soft-shelled gelatin
type containing, for example, surfactants, lubricants, and inert
fillers, such as lactose, sucrose, calcium phosphate, and corn
starch. Tablet forms can include one or more of the following:
lactose, sucrose, mannitol, corn starch, potato starch, alginic
acid, microcrystalline cellulose, acacia, gelatin, guar gum,
colloidal silicon dioxide, croscarmellose sodium, talc, magnesium
stearate, calcium stearate, zinc stearate, stearic acid, and other
excipients, colorants, diluents, buffering agents, disintegrating
agents, moistening agents, preservatives, flavoring agents, and
pharmacologically compatible carriers. Lozenge forms can comprise
the active ingredient in a flavor, usually sucrose and acacia or
tragacanth, as well as pastilles comprising the active ingredient
in an inert base, such as gelatin and glycerin, or sucrose and
acadia, emulsions, and gels containing, in addition to the active
ingredient, such carriers as are known in the art.
[0039] Formulations suitable for parenteral administration include
aqueous and non-aqueous, isotonic sterile injection solutions,
which can contain anti-oxidants, buffers, bacteriostats, and
solutes that render the formulation isotonic with the blood of the
intended recipient, and aqueous and non-aqueous sterile suspensions
that can include suspending agents, solubilizers, thickening
agents, stabilizers, and preservatives. The compound can be
administered in a physiologically acceptable diluent in a
pharmaceutical carrier, such as a sterile liquid or mixture of
liquids, including water, saline, aqueous dextrose and related
sugar solutions, an alcohol, such as ethanol, isopropanol, or
hexadecyl alcohol, glycols, such as propylene glycol or
polyethylene glycol such as poly(ethyleneglycol) 400, glycerol
ketals, such as 2,2-dimethyl-1,3-dioxolane-4-methanol, ethers, an
oil, a fatty acid, a fatty acid ester or glyceride, or an
acetylated fatty acid glyceride with or without the addition of a
pharmaceutically acceptable surfactant, such as a soap or a
detergent, suspending agent, such as pectin, carbomers,
methylcellulose, hydroxypropylmethylcellulose, or
carboxymethylcellulose, or emulsifying agents and other
pharmaceutical adjuvants.
[0040] Oils, which can be used in parenteral formulations include
petroleum, animal, vegetable, or synthetic oils. Specific examples
of oils include peanut, soybean, sesame, cottonseed, corn, olive,
petrolatum, and mineral. Suitable fatty acids for use in parenteral
formulations include oleic acid, stearic acid, and isostearic acid.
Ethyl oleate and isopropyl myristate are examples of suitable fatty
acid esters. Suitable soaps for use in parenteral formulations
include fatty alkali metal, ammonium, and triethanolamine salts,
and suitable detergents include (a) cationic detergents such as,
for example, dimethyldialkylammonium halides, and alkylpyridinium
halides, (b) anionic detergents such as, for example, alkyl, aryl,
and olefin sulfonates, alkyl, olefin, ether, and monoglyceride
sulfates, and sulfosuccinates, (c) nonionic detergents such as, for
example, fatty amine oxides, fatty acid alkanolamides, and
polyoxyethylene polypropylene copolymers, (d) amphoteric detergents
such as, for example, alkyl .beta.-aminopropionates, and
2-alkylimidazoline quaternary ammonium salts, and (e) mixtures
thereof.
[0041] The parenteral formulations typically contain from about
0.5% to about 25% by weight of the active ingredient in solution.
Suitable preservatives and buffers can be used in such
formulations. In order to minimize or eliminate irritation at the
site of injection, such compositions may contain one or more
nonionic surfactants having a hydrophile-lipophile balance (HLB) of
from about 12 to about 17. The quantity of surfactant in such
formulations ranges from about 5% to about 15% by weight. Suitable
surfactants include polyethylene sorbitan fatty acid esters, such
as sorbitan monooleate and the high molecular weight adducts of
ethylene oxide with a hydrophobic base, formed by the condensation
of propylene oxide with propylene glycol.
[0042] Pharmaceutically acceptable excipients are also well-known
to those who are skilled in the art. The choice of excipient will
be determined in part by the particular compound, as well as by the
particular method used to administer the composition. Accordingly,
there is a wide variety of suitable formulations of the
pharmaceutical composition of the present disclosure. The following
methods and excipients are merely exemplary and are in no way
limiting. The pharmaceutically acceptable excipients preferably do
not interfere with the action of the active ingredients and do not
cause adverse side-effects. Suitable carriers and excipients
include solvents such as water, alcohol, and propylene glycol,
solid absorbants and diluents, surface active agents, suspending
agent, tableting binders, lubricants, flavors, and coloring
agents.
[0043] The formulations can be presented in unit-dose or multi-dose
sealed containers, such as ampules and vials, and can be stored in
a freeze-dried (lyophilized) condition requiring only the addition
of the sterile liquid excipient, for example, water, for
injections, immediately prior to use. Extemporaneous injection
solutions and suspensions can be prepared from sterile powders,
granules, and tablets. The requirements for effective
pharmaceutical carriers for injectable compositions are well known
to those of ordinary skill in the art. See Pharmaceutics and
Pharmacy Practice, J. B. Lippincott Co., Philadelphia, Pa., Banker
and Chalmers, Eds., 238-250 (1982) and ASHP Handbook on Injectable
Drugs, Toissel, 4.sup.th ed., 622-630 (1986).
[0044] Suitable pharmaceutical carriers are described in
Remington's Pharmaceutical Sciences, Mack Publishing Company, a
standard reference text in this field.
[0045] The dose administered to an animal, particularly a human, in
the context of the present disclosure should be sufficient to
affect a therapeutic response in the animal over a reasonable time
frame. One skilled in the art will recognize that dosage will
depend upon a variety of factors including a condition of the
animal, the body weight of the animal, as well as the severity and
stage of the condition being treated.
[0046] A suitable dose is that which will result in a concentration
of the active agent in a patient which is known to affect the
desired response. The preferred dosage is the amount which results
in maximum inhibition of the condition being treated, without
unmanageable side effects.
[0047] The size of the dose also will be determined by the route,
timing and frequency of administration as well as the existence,
nature, and extend of any adverse side effects that might accompany
the administration of the compound and the desired physiological
effect.
[0048] Useful pharmaceutical dosage forms for administration of the
compounds according to the present disclosure can be illustrated as
follows:
Hard Shell Capsules
[0049] A large number of unit capsules are prepared by filling
standard two-piece hard gelatine capsules each with 100 mg of
powdered active ingredient, 150 mg of lactose, 50 mg of cellulose
and 6 mg of magnesium stearate.
Soft Gelatin Capsules
[0050] A mixture of active ingredient in a digestible oil such as
soybean oil, cottonseed oil or olive oil is prepared and injected
by means of a positive displacement pump into molten gelatin to
form soft gelatin capsules containing 100 mg of the active
ingredient. The capsules are washed and dried. The active
ingredient can be dissolved in a mixture of polyethylene glycol,
glycerin and sorbitol to prepare a water miscible medicine mix.
Tablets
[0051] A large number of tablets are prepared by conventional
procedures so that the dosage unit was 100 mg of active ingredient,
0.2 mg. of colloidal silicon dioxide, 5 mg of magnesium stearate,
275 mg of microcrystalline cellulose, 11 mg. of starch, and 98.8 mg
of lactose. Appropriate aqueous and non-aqueous coatings may be
applied to increase palatability, improve elegance and stability or
delay absorption.
Immediate Release Tablets/Capsules
[0052] These are solid oral dosage forms made by conventional and
norovirusel processes. These units are taken orally without water
for immediate dissolution and delivery of the medication. The
active ingredient is mixed in a liquid containing ingredient such
as sugar, gelatin, pectin and sweeteners. These liquids are
solidified into solid tablets or caplets by freeze drying and solid
state extraction techniques. The drug compounds may be compressed
with viscoelastic and thermoelastic sugars and polymers or
effervescent components to produce porous matrices intended for
immediate release, without the need of water.
[0053] The term "comprising" (and its grammatical variations) as
used herein is used in the inclusive sense of "having" or
"including" and not in the exclusive sense of "consisting only of."
The terms "a" and "the" as used herein are understood to encompass
the plural as well as the singular.
[0054] All publications, patents and patent applications cited in
this specification are herein incorporated by reference, and for
any and all purpose, as if each individual publication, patent or
patent application were specifically and individually indicated to
be incorporated by reference. In the case of inconsistencies, the
present disclosure will prevail.
[0055] The foregoing description of the disclosure illustrates and
describes the present disclosure. Additionally, the disclosure
shows and describes only the preferred embodiments but, as
mentioned above, it is to be understood that the disclosure is
capable of use in various other combinations, modifications, and
environments and is capable of changes or modifications within the
scope of the concept as expressed herein, commensurate with the
above teachings and/or the skill or knowledge of the relevant
art.
[0056] The embodiments described hereinabove are further intended
to explain best modes known of practicing it and to enable others
skilled in the art to utilize the disclosure in such, or other,
embodiments and with the various modifications required by the
particular applications or uses. Accordingly, the description is
not intended to limit it to the form disclosed herein. Also, it is
intended that the appended claims be construed to include
alternative embodiments.
* * * * *